Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting

References

• Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet. 2018;392(10151):971–984.
   PubMed Web of Science ®Google Scholar
• Mandalà M, Voit C. Targeting BRAF in melanoma: biological and clinical challenges. Crit Rev Oncol Hematol. 2013;87(3):239–255.
   PubMed Web of Science ®Google Scholar
• Spagnolo F, Ghiorzo P, Orgiano L, et al. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther. 2015;8:157–168.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–114.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–1703.
   PubMed Web of Science ®Google Scholar
• Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631–1639.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315–1327.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–1260.
   PubMed Web of Science ®Google Scholar
• Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2017;28(suppl_4):iv119–iv142.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365.
   PubMed Web of Science ®Google Scholar
• Livingstone E, Zimmer L, Vaubel J, et al. BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. Chinese Clin Oncol. 2014;3(3):29.
   PubMedGoogle Scholar
• Mincu RI, Mahabadi AA, Michel L, et al. Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(8):1–13.
   Web of Science ®Google Scholar
• Shah RR, Morganroth J. Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk/benefit. Drug Safety. 2015;38(8):693–710.
   PubMed Web of Science ®Google Scholar
• Bronte E, Bronte G, Novo G, et al. Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. Pharmacol Ther. 2018;192:65–73.
   PubMed Web of Science ®Google Scholar
• Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev. 2010;90(4):1507–1546.
   PubMed Web of Science ®Google Scholar
• Rossello X, Yellon DM. The RISK pathway and beyond. Basic Res Cardiol. 2018;113(1):1–5.
   PubMed Web of Science ®Google Scholar
• Bronte E, Bronte G, Novo G, et al. What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget. 2015;6(34):35589–35601.
   PubMedGoogle Scholar
• Bueno OF, Molkentin JD. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res. 2002;91(9):776–781.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, ElHalawani H, Ahmed H. Risk of selected cardiovascular toxicities in patients with cancer treated with MEK inhibitors: a comparative systematic review and meta-analysis. J Glob Oncol. 2015;1(2):73–82.
   PubMedGoogle Scholar
• Chen-Scarabelli C, McRee C, Leesar MA, et al. Comprehensive review on cardio-oncology: role of multimodality imaging. J Nucl Cardiol. 2017;24(3):906–935.
   PubMed Web of Science ®Google Scholar
• Guha A, Jain P, Fradley MG, et al. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: cross-sectional and longitudinal analysis using two large national registries. Cancer Med. 2021;10(12):3862–3872.
   PubMed Web of Science ®Google Scholar
• Ellebaek E, Svane IM, Schmidt H, et al. The Danish metastatic melanoma database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. Cancer Epidemiol. 2021;73: 101943.
   PubMed Web of Science ®Google Scholar
• Jensen MM, Haase C, Zerahn B. Interstudy repeatability of left and right ventricular volume estimations by serial-gated tomographic radionuclide angiographies using a cadmium-zinc-telluride detector gamma camera. Clin Physiol Funct Imaging. 2015;35(6):418–424.
   PubMed Web of Science ®Google Scholar
• Rydberg J, Andersen J, Haarmark C, et al. The influence of anthropometric and basic circulatory variables on count rate in cadmium-zinc-telluride SPECT gated radionuclide angiography. J Nucl Cardiol. 2019;26(6):1974–1980.
   PubMed Web of Science ®Google Scholar
• Hansen NL, Haarmark C, Zerahn B. Ventricular peak emptying and filling rates measured by gated tomographic radionuclide angiography using a cadmium–zinc–telluride SPECT camera in chemotherapy-naïve cancer patients. J Nucl Cardiol. 2020;27(4):1193–1201.
   PubMed Web of Science ®Google Scholar
• Khouri MG, Douglas PS, Mackey JR, et al. Cancer therapy-induced cardiac toxicity in early breast cancer addressing the unresolved issues. Circulation. 2012;126(23):2749–2763.
   PubMed Web of Science ®Google Scholar
• Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–939.
   PubMed Web of Science ®Google Scholar
• Perez IE, Alam ST, Hernandez GA, et al. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol. 2019;13:117954681986644.
   Web of Science ®Google Scholar
• Haarmark C, Haase C, Jensen MM, et al. Pre-chemotherapy values for left and right ventricular volumes and ejection fraction by gated tomographic radionuclide angiography using a cadmium-zinc-telluride detector gamma camera. J Nucl Cardiol. 2016;23(1):87–97.
   PubMed Web of Science ®Google Scholar
• Berger M, Amini-Adlé M, Maucort-Boulch D, et al. Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: a retrospective analysis. Cancer Med. 2020;9(8):2611–2620.
   PubMed Web of Science ®Google Scholar
• Erbel R, Schweizer P, Krebs W, et al. Effects of heart rate changes on left ventricular volume and ejection fraction: a 2-dimensional echocardiographic study. Am J Cardiol. 1984;53(4):590–597.
   PubMed Web of Science ®Google Scholar
• Von Haehling S, Lainscak M, Kung T, et al. Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study. Arch Med Sci. 2013;9(2):261–267.
   PubMed Web of Science ®Google Scholar
• Anker MS, Ebner N, Hildebrandt B, et al. Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study. Eur J Heart Fail. 2016;18(12):1524–1534.
   PubMed Web of Science ®Google Scholar
• Knispel S, Zimmer L, Kanaki T, et al. The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma. Expert Opin Drug Saf. 2018;17(1):73–87.
   PubMed Web of Science ®Google Scholar
• Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015;7(2):122–136.
   PubMed Web of Science ®Google Scholar
• Totzeck M, Schuler M, Stuschke M, et al. Cardio-oncology – strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280:163–175.
   PubMed Web of Science ®Google Scholar